Old Web
English
Sign In
Acemap
>
authorDetail
>
Melanie E Royce
Melanie E Royce
Food and Drug Administration
Medicine
Internal medicine
Oncology
Fulvestrant
Breast cancer
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis.
2021
Journal of Clinical Oncology
Jennifer J Gao
Joyce Cheng
Tatiana M. Prowell
Erik Bloomquist
Shenghui Tang
Suparna B. Wedam
Melanie E Royce
Danielle Krol
Christy Osgood
Gwynn Ison
Rajeshwari Sridhara
Richard Pazdur
Julia A. Beaver
Laleh Amiri-Kordestani
Show All
Source
Cite
Save
Citations (0)
Overall Survival in Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Treated with a CDK 4/6 Inhibitor Plus Fulvestrant: A U.S. Food and Drug Administration Pooled Analysis
2021
Social Science Research Network
Jennifer J. Gao
Joyce Cheng
Tatiana M. Prowell
Erik Bloomquist
Shenghui Tang
Suparna Wedam
Melanie E Royce
Danielle Krol
Christy Osgood
Gwynn Ison
Rajeshwari Sridhara
Richard Pazdur
Julia A. Beaver
Laleh Amiri-Kordestani
Show All
Source
Cite
Save
Citations (0)
FDA Oncology Center of Excellence landscape analysis of real-world data submissions for oncology drugs.
2021
Journal of Clinical Oncology
Donna Rivera
Jennifer J. Lee
Melanie E Royce
Paul G. Kluetz
Show All
Source
Cite
Save
Citations (0)
1